Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study

Pulmonary Pharmacology and Therapeutics

Volumn 35, Issue , 2015, Pages 42-49

  Santus, Pierachille ^a   Radovanovic, Dejan ^a   Di Marco, Fabiano ^a   Raccanelli, Rita ^a   Valenti, Vincenzo ^a   Centanni, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Aclidinium bromide; Bronchodilator; COPD; Dyspnoea; Glycopyrronium bromide; Hyperinflation

Indexed keywords

ACLIDINIUM BROMIDE; GLYCOPYRRONIUM BROMIDE; BRONCHODILATING AGENT; GLYCOPYRRONIUM; TROPANE DERIVATIVE;

ADULT; AGED; AIRWAY RESISTANCE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; HUMAN; HYPERINFLATION; INTRATHORACIC GAS VOLUME; LUNG VENTILATION; MALE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; RESPIRATORY TRACT PARAMETERS; VISUAL ANALOG SCALE; BIOASSAY; CLINICAL TRIAL; COMPARATIVE STUDY; LUNG; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSPNEA; ENDPOINT DETERMINATION; FEMALE; GLYCOPYRROLATE; HUMANS; LUNG; MALE; MIDDLE AGED; PLETHYSMOGRAPHY; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESIDUAL VOLUME; RESPIRATORY FUNCTION TESTS; TROPANES;

EID: 84959309265     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2015.11.001     Document Type: Article

References (33)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 16 Apr 2015, http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf.
2. Timmins S.C., Diba C., Farrow C.E., Schoeffel R.E., Berend N., Salome C.M., et al. The relationship between airflow obstruction, emphysema extent, and small airways function in COPD. Chest 2012, 142:312-319.
3. Bommart S., Marin G., Bourdin A., Molinari N., Klein F., Hayot M., et al. Relationship between CT air trapping criteria and lung function in small airway impairment quantification. BMC Pulm. Med 2014, 14:29.
4. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., Buzatu L., et al. The nature of small- airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med 2004, 350:2645-2653.
5. Nagelmann A., Tonnov Ä Laks T., Sepper R., Prikk K. Lung dysfunction of chronic smokers with no signs of COPD. COPD 2011, 8(3):189-195.
6. Milic-Emili J. Does mechanical injury of the peripheral airways play a role in the genesis of COPD in smokers?. COPD 2004, 1(1):85-92.
7. Burgel P.R., Bourdin A., Chanez P., Chabot F., Chaouat A., Chinet T., et al. Update on the roles of distal airways in COPD. Eur. Respir. Rev 2011, 20:7-22.
8. Fowler W.S. Lung function studies; uneven pulmonary ventilation in normal subjects and in patients with pulmonary disease. J. Appl. Physiol 1949, 2:283-299.
9. Aliverti A., Macklem P.T. The major limitation to exercise performance in COPD is inadequate energy supply to the respiratory and locomotor muscles. J. Appl. Physiol 1985, 2008(105):749-751.
10. O'Donnell D.E., Webb K.A. The major limitation to exercise performance in COPD is dynamic hyperinflation. J. Appl. Physiol 2008, 105:753-755.
11. D'Angelo E., Santus P., Civitillo M.F., Centanni S., Pecchiari M. Expiratory flow-limitation and heliox breathing in resting and exercising COPD patients. Respir. Physiol. Neurobiol 2009, 169:291-296.
12. Santus P., Centanni S., Verga M., Di Marco F., Matera M.G., Cazzola M. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. Respir. Med 2006, 100:1277-1288.
13. Santus P., Radovanovic D., Henchi S., Di Marco F., Centanni S., D'Angelo E., et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir. Physiol. Neurobiol 2014, 197:36-45.
14. Cazzola M., Page C., Matera M.G. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm. Pharmacol. Ther 2013, 26(3):307-317. 10.1016/j.pupt.2012.12.006.
15. Gavaldà A., Gras J., Llupià J., Aubets J., Beleta J., Llenas J. Aclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile. Life Sci 2012, 90(7-8):301-305. 10.1016/j.lfs.2011.12.002.
16. Jones W.P. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Adv. Ther 2013, 30(4):354-368. 10.1007/s12325-013-0019-2.
17. Molimard M., D'Andrea P. Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile. Expert Rev. Clin. Pharmacol 2013, 6(5):503-517. 10.1586/17512433.2013.828419.
18. Beeh K.M., Singh D., Di Scala L., Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int. J. Chron. Obstruct Pulmon Dis 2012, 7:503-513.
19. Maltais F., Celli B., Casaburi R., Porszasz J., Jarreta D., Seoane B., et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir. Med 2011, 105(4):580-587.
20. Pellegrino R., Viegi G., Brusasco V., Crapo R.O., Burgos F., Casaburi R., et al. Interpretative strategies for lung function tests. Eur. Respir. J. 2005, 26:948-968.
21. Wanger J., Clausen J.L., Coates A., Pedersen O.F., Brusasco V., Burgos F., et al. Standardisation of the measurement of lung volumes. Eur. Respir. J. 2005, 26:511-522.
22. MacIntyre N., Crapo R.O., Viegi G., Johnson D.C., van der Grinten C.P.M., Brusasco V., et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur. Respir. J. 2005, 26:720-735.
23. Hughes J.M., Pride N.B. Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components. Am. J. Respir. Crit. Care Med 2012, 186:132-139.
24. Ries A.L. Minimally clinically important difference for the UCSD Shortness of breath questionnaire, borg scale, and visual analog scale. COPD 2005, 2:105-110.
25. American Thoracic Society Dyspnea. Mechanisms, assessment, and management: a consensus statement. Am. J. Respir. Crit. Care Med 1999, 159:321-340.
26. Beeh K.M., Watz H., Puente-Maestu L., de Teresa L., Jarreta D., Caracta C., et al. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial. BMC Pulm. Med 2014, 14:209.
27. O'Donnell D.E., Flüge T., Gerken F., Hamilton A., Webb K., Aguilaniu B., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004, 23:832-840.
28. Rossi A., Centanni S., Cerveri I., Gulotta C., Foresi A., Cazzola M., et al. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir. Med 2012, 106(1):84-90. 10.1016/j.rmed.2011.09.006.
29. Gennimata S.A., Palamidas A., Karakontaki F., Kosmas E.N., Koutsoukou A., Loukides S., et al. Pathophysiology of evolution of small airways disease to overt COPD. COPD 2010, 7:269-275.
30. Neder J.A., O'Donnell C.D., Cory J., Langer D., Ciavaglia C.E., Ling Y., et al. Ventilation distribution heterogeneity at rest as a marker of exercise impairment in mild-to-advanced COPD. COPD 2015 Jun, 12(3):249-256. instead COPD 2014, [Epub ahead of print].
31. Mikamo M., Shirai T., Mori K., Shishido Y., Akita T., Morita S., et al. Predictors of phase III slope of nitrogen single-breath washout in COPD. Respir. Physiol. Neurobiol 2013, 189(1):42-46. 10.1016/j.resp.2013.06.018.
32. Noseda A., Schmerber J., Prigogine T., Yernault J.C. How do patients with either asthma or COPD perceive acute bronchodilation?. Eur. Respir. J. 1993, 6:636-644.
33. Rogliani P., Calzetta L., Ora J., Lipsi R., Segreti A., Matera M.G., et al. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. Eur. J. Pharmacol 2015, 761:383-390.